SCINTIMUN

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United Kingdom

Active ingredients

The drug SCINTIMUN contains one active pharmaceutical ingredient (API):

1 Technetium ⁹⁹ᵐTc antigranulocyte antibody UNII 538316W9ZU - BESILESOMAB

Read about Technetium ⁹⁹ᵐTc antigranulocyte antibody

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
SCINTIMUN Kit for radiopharmaceutical preparation	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
V09HA03	Technetium (99mTc) antigranulocyte antibody	V Various → V09 Diagnostic radiopharmaceuticals → V09H Inflammation and infection detection → V09HA Technetium (99mTc) compounds
Discover more medicines within V09HA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1458907, 1458918
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 09602002
Country: FR	Base de données publique des médicaments	Identifier(s): 68516450
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 394714
Country: IT	Agenzia del Farmaco	Identifier(s): 040281014, 040281026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1052911, 1052912
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100316444